[1] |
LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo.
Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
|
[2] |
ZHANG Jian, FANG Huihua.
Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
|
[3] |
BAI Zhaofang, ZHAN Xiaoyan, YAO Qing, CHEN Simin, ZHAO Xu, XIAO Xiaohe.
Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: disease-syndrome-based toxicology
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 6-14.
|
[4] |
GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe.
Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
|
[5] |
GAO Yuan, SHI Wei, XIAO Xiaohe, BAI Zhaofang, WANG Jiabo.
Research progress on the animal models of idiosyncratic drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 33-39.
|
[6] |
ZHANG Jingsheng, JI Zuen, PANG Bo, XU Yingli, CAO Shan, ZHANG Yu, SUN Qiyue, SUN Jing, LI Shuran, ZHANG Wei, ZHAO Ronghua, CUI Xiaolan.
Discussion on traditional Chinese medicine theory and modern pharmacology of Xuanfei Baidu decoction for treating novel coronavirus infection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 55-58.
|
[7] |
LI Shuran, GUO Shanshan, JI Zuen, ZHANG Wei, CUI Xiaolan.
Research status of cognitive dysfunction after SARS-CoV-2 infection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 59-64.
|
[8] |
HE Jia, JIN Yan, ZHAO Yuyang, ZHOU Junhui, LI Xiaolin, YUAN Yuan, FU Lu.
Research progress in methods for toxicity-decreasing processing of toxic herbal traditional Chinese medicines
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1064-1070.
|
[9] |
DING Zihe, ZHANG Yanqiong, LIN Na.
Component-effect/toxicity-target correlations of Tripterygium wilfordii in terms of lipid metabolism
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 489-495.
|
[10] |
LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping.
Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
|
[11] |
SHEN Pan, SUN Dezhi, ZHOU Wei, GAO Yue.
Research progress in toxicity prediction of traditional Chinese medicines
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 473-479.
|
[12] |
LI Shuran, GUO Shanshan, CUI Xiaolan.
Research progress in correlations between herpes simplex virus-1 and Alzheimer's disease and in the prevention and treatment of herpes simplex virus-1 with traditional Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 258-261.
|
[13] |
WANG Guanjie, DU Shifang, LIU Baosheng, HAN Jiayan, WANG Zhenhua, LU Changfei.
107 cases of liver injury caused by traditional Chinese medicines
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 331-333.
|
[14] |
XU Shuai, ZHANG Ling, ZHAO Yuqing, YANG Yidian, BIAN Haoyu, ZHANG Liping.
Advances in multi-target intervention in vascular endothelial injury in metabolic syndrome by traditional Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 353-359.
|
[15] |
NEI Qian, HUANG Ailing, ZHANG Hongcai, ZHAO Jue, ZHANG Delai, XIE Wen.
Analysis of one case of green urine caused by Indigo Naturalis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 219-220.
|